Circassia Share Discussion Threads

[gymratt] 10/2/2020 12:12

It all makes for another buying opportunity though! ;@)

[onedayrodders] 10/2/2020 12:00

yes some technical round number resistance selling but also, I agree with an earlier comment that our expected sales push in China has got to be being held up given situation over there currently.

I guess some selling as a result of that too.

[100egs] 10/2/2020 09:46

some resistance here at 26 ish levels, managed to add a few earlier at 25.6 hopefully we can take another run at 30p from here.

[mad foetus] 10/2/2020 09:11

Time to buy back the traders

[bc4] 09/2/2020 22:06

andyview, He knows nothing take no notice of him he appeared from nowhere and will soon disappear to his bunker

[andyview] 09/2/2020 21:51

Richard Griffiths has been and still is a major shareholder in Silence Therapeutics, still over 23% I believe. He’s been there for a good few years so no reason to fear his investment here will be anything other than strategic and long term ...aimho

Gla - fill ya boots at this level for me

[andyview] 09/2/2020 21:37

There nothing new here in the results from BeyondAir, the position from CIR will be defended:

RNS Number : 4542X

Circassia Pharmaceuticals Plc

19 December 2019

Update on Circassia's Licensing Agreement with BeyondAir Inc. for LungFit PH

Oxford, UK - 19 December 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, provides an update on its licensing agreement with BeyondAir Inc. (previously AIT Therapeutics Inc.) for the commercial rights to the late-stage ventilator-compatible nitric oxide product LungFit PH (previously AirNOvent) in the USA and China.

Circassia has received a notice from BeyondAir stating that it has terminated the agreement for material breach. Circassia refutes the allegations in the strongest terms and believes there are no grounds to terminate the agreement. The Company will enforce its rights under the agreement and defend its position vigorously.

[catswhiskas] 09/2/2020 20:17

Indeed this is in big trouble on Monday.

Man the lifeboats Mr Lightowler Women and Children first 😳
Dont forget to load Griffiths into the life boat with a hole in it !

[onedayrodders] 09/2/2020 18:43

now now manc ...take up your issue with someuwin direct, don't pollute other threads just for the sake of it because it makes you no better than him.

[manc10] 09/2/2020 18:42

Great point someuwin

Funds didn't think it worth buying either

A revisit assured

[manc10] 09/2/2020 18:41

Great point someuwin

Funds didn't think it worth buying either

A revisit assured

[manc10] 09/2/2020 18:34

this is in trouble monday sumuwin sumulose

[bjfanc] 09/2/2020 18:13

I just don't see how Beyond air can expect to keep the $10.5 million dollars received in milestones from Circassia. You'd like to think that negotiations are taking place and hopefully more details released of this alleged material breach.

[74tom] 08/2/2020 09:03

Thanks for the heads up Eeza, it’s the SEC filing that I was specifically waiting for;



This provides some interesting info;

Firstly it confirms that they had sold all of their Circassia shares by 31/12, at 30/09 they still had $1.9m remaining, or around 10m shares (page 16 of the link below) this was another overhang that was somewhat under the radar. No surprise they sold all the shares prior to terminating the agreement!



Page 32 has the following statement;

“We may be subject to certain claims by Circassia.”

“In connection the termination of our license agreement with Circassia, we may be subject to certain claims by Circassia. Adverse outcomes in some or all of these claims may negatively affect our ability to conduct our business. However, as of the date hereof, we cannot estimate the likelihood that we will be subject to any claims or the effects thereof on our business and operations.”

So all remains up in the air, however I really think they’ve acted terribly in this situation, to be selling down $2m of circassia shares in the months immediately prior to them terminating a 10 month old agreement looks very suspect in my opinion.

Hopefully this can be cleared up ASAP, as alongside the concerns about our China business it is the only overhang on the share right now.

A comment regarding the Chinese supply chain impact would be most welcome and if positive would see us through 30p, personally I think that’s the reason for the pull back & it could continue pending an update.

[eeza] 08/2/2020 07:32

Beyondair's results also say:

"Recent Highlights and Upcoming Milestones

Raised $11.5 million in gross proceeds via an offering of 3,152,985 shares of common stock in December 2019.

Announced an exclusive five-year global supply agreement for NO and NO2 (Nitrogen Dioxide) calibration gas with MESA Specialty Gases & Equipment. The five-year term is to begin on the earlier of FDA approval for the LungFit™ PH system or December 31, 2020.

Terminated for material breach its agreement with Circassia Pharmaceuticals PLC for the commercial rights to LungFit™ PH in the United States and China for use in the hospital setting at NO concentrations <80 ppm. Beyond Air is evaluating options for the commercialization of LungFit™ PH, which is still on track for the fourth quarter of calendar 2020 in the United States."

[pro_s2009] 08/2/2020 06:15

BeyondAir results



.

[onedayrodders] 07/2/2020 17:10

the bowl mauy not be smooth on the way up but wasn't on the way down so not concerned.

I think a few got a bot twitchy with this (tedious) hesitation at the round number 30p selling / resistance

[andyview] 07/2/2020 16:25

It is a really good appointment

Gla

[bettyswollox] 07/2/2020 16:19

This did it for me - from Investor's Chronicle:
CIP Merchant Capital’s most recent investment was made only last month when the company acquired 12.8m shares, or 3.4 per cent of the equity, in Aim-traded Circassia Pharmaceuticals (CIR), a speciality biopharmaceutical company focused on allergy and respiratory diseases. Circassia’s directors expect revenues for the 2019 financial year to be in the middle of their previously issued guidance of £60m to £65m, representing significant growth compared with the previous year (2018: £48.3m). The board also expects to report growth in sales of both NIOX (asthma management product) and Tudorza (maintenance treatment of chronic obstructive pulmonary disease (COPD)), and a modest contribution from Duaklir, another COPD product launched in October 2019.

It has been a well-timed purchase as the holding is already showing an £800,000 paper profit on CIP Merchant Capital’s £2.8m purchase price. Circassia’s year-end cash position was better than expected, helped in part by the timing of certain payments and third-party rebates. Also, it will not have gone unnoticed that Michael Roller, the former finance director of Bioquell, the star of my 2016 Bargain Shares portfolio – a 372 per cent total return on the holding by the time the company was taken over in January 2019 – has just been appointed Circassia’s new finance director.

[andyview] 07/2/2020 15:45

Good luck to you both, i'm fully loaded but would love spare funds on this pullback.

dyor of course